Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of an underwritten public offering of 6,670,000 shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $40,020,000 million, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 45-day o

Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock

Virpax has exclusive worldwide rights to non-opioid, non-addictive analgesic delivery systems. The company's pipeline has candidates eligible for abbreviated regulatory pathway as well as an OTC.

Virpax: Targeting Pain At Its Source

BERWYN, Pa.--(BUSINESS WIRE)-- #PAINWeek--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV. The following poster from Virpax will be presented on Thursday, September 9th from 6:30 p.m. – 8:30 p.m. PST: Title: Enkephalin as a Potential Analgesic and CNS Modulator Presenter: Jeffrey A. Gudin, MD, EVP, Chief Me

Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement

Virpax Announces MMS019 Manufacturing and Supply Agreement

NanoVibronix

Bit Digital, Inc

Support.com

Cardiol Therapeutics

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

On Wednesday, Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) shares soared more than 97% before pulling back later for a net intraday gain of 43%. The stock is now up more than 470% from its Monday close following Tuesday's events.

Should you invest in Virpax Pharma as stock soars more than 40%?

Shares of VRPX stock continue to blow up on Wednesday after Virpax Pharmaceuticals' massive business announcement on Tuesday. The post VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly appeared first on InvestorPlace.

VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly

Shares of Virpax Pharmaceuticals Inc. VRPX, +57.46% rocketed for a second straight day on heavy volume, after the company announced an upbeat pre-investigational new drug response from the Food and Drug Administration on its product to inhibit SARS-CoV-2 and the flu. The stock shot up 53.6% in morning trading, after soaring 265.5% on Tuesday, to mark a two-day gain of 461.4%.

Virpax's stock rockets nearly 5-fold in 2 days after upbeat FDA response to its SARS-CoV-2 inhibitor

The shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) increased 265.48%. This is why it happened.

Virpax Pharmaceuticals Shares Increased 265.48%: Why It Happened

Virpax stock reached its highest price since going public earlier this year after the FDA issued guidance on a potential anti-viral product

Virpax soars 292% after receiving initial FDA guidance on its treatment for SARS and flu

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administration for MMS019. MMS019 is Virpax Pharmaceuticals patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product.

Why Virpax Pharmaceuticals Shares Are Soaring Today

Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) said on Tuesday it received a written pre-IND (investigational new drug) response from the U.S. FDA (Food and Drug Administration) for MMS019 that supports further research on its application as an intranasal protective that restricts transmission of viruses to others. Virpax to seek an NDA for MMS019 The Pennsylvania-based company […] The post Here's why Virpax Pharmaceuticals is up 280% on Tuesday appeared first on Invezz.

Here's why Virpax Pharmaceuticals is up 280% on Tuesday

Virpax Pharma (VRPX) stock is rocketing higher on Tuesday after getting a response from the FDA concerning an anti-viral barrier product. The post VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250% appeared first on InvestorPlace.

VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250%

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019. The drug candidate is a high-density molecular masking spray under development for use as an anti-viral barrier product.

Why Virpax Pharmaceuticals Stock Flying Higher?

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has received a written pre-investigational new drug (pre-IND) response from the U.S. Food and Drug Administration (FDA) for MMS019, its patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product. Virpa

Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended June 30, 2021, and other recent developments. “We continue to advance our product candidate pipeline focused on pain, CNS and anti-viral indications. Two of our product candidates, Epoladerm™ and Probudur™, will utilize an accelerated 505(b)(2) pathway and are currently being funded through proceeds from our initial public offering wh

Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors. “I am pleased that we are adding two such highly knowledgeable professionals to our Board of Directors. Each of them has valuable experience and we look forward to their contributions,” commented Virp

Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F.

The stock price of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) increased by 30.62%. This is why it happened.

VRPX Stock Increased 30.62%: Details You Should Know

The stock price of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) increased by over 60% during intraday trading. This is why it happened.

VRPX Stock Increases 61% Intraday: Why It Happened

The stock price of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) increased by over 50% during intraday trading. This is why it happened.

Virpax Pharmaceuticals Stock Price Increases Over 55%: Why It Happened

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today is providing a progress update on its pipeline of product candidates following the Company's initial public offering (the “IPO”) in mid-February of 2021. Chairman and CEO Anthony P. Mack commented, “Our goal following our IPO was to become a clinical stage company as quickly as possible while preserving our cash and utilizing grants to fund product development efforts where appropriate. T

Virpax Pharmaceuticals Provides Progress Update on Product Candidates

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), today announced that the Investigational New Drug (IND) Application enabling studies for Envelta™ being performed under a Cooperative Research and Development Agreement (CRADA) entered into by Virpax and the National Center for Advancing Translational Sciences (NCATS) for chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic St

Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET. Anthony Mack, Chairman and CEO of Virpax, will be giving the presentation. Event: Virpax Pharmaceuticals Presentation at the LD Micro Invitational

Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. “We successfully completed our initial public offering (IPO) of 1,800,000 shares of our common stock in mid-February and immediately began our IND enabling studies for Epoladerm™ and Envelta™, so that we can meet with the FDA and initiate first-in-human trials. Additionally, we recently r

Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #licensing--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets. Torreya is a global investment bank that has facilitated more than $100 billion worth of transactions in the life sciences industry since its inception in 2007. “We are excited to be working with

News for Virpax Pharmaceuticals Stock (VRPX)